Last reviewed 2026-04-20 · How we verify

Elranatamab (PF-06863135) (elranatamab-pf-06863135)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Neutropenia
• Anaemia
• Diarrhoea
• Cytokine release syndrome
• Pyrexia
• Leukopenia
• Fatigue
• Thrombocytopenia
• Hypokalaemia
• Hypogammaglobulinaemia
• Decreased appetite
• Nausea

Key clinical trials

• A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
• A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (PHASE1)
• A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) (PHASE1)
• MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
• A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy (PHASE3)
• ELISA in Relapsed/Refractory MM (PHASE2)
• A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects (PHASE1)
• MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Elranatamab (PF-06863135) CI brief — competitive landscape report
• Elranatamab (PF-06863135) updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI